Onco Wiki / Indication

T-Cell Prolymphocytic Leukemia · line 2 · Venetoclax + alemtuzumab combination for r/r T-PLL (investigational)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Notes

STUB. Investigational; refer to clinical trial when feasible. Major UA access barrier for both components. Always plan as bridge to alloSCT.

Used By

Algorithms

• ALGO-T-PLL-2L - ALGO-T-PLL-2L